Dompé

Focus: Dompé is an Italian biotechnology company headquartered in L'Aquila with a diversified pipeline spanning biologics, small molecules, and OTC products across ophthalmology, metabolic diseases, oncology, respiratory, and infectious disease indications.

Ophthalmology Metabolic Diseases Oncology Respiratory

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Dompé

AI assessmentNot Hiring

No open roles listed right now. Follow Dompé to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

OXERVATE®

Neurotrophic Keratitis

Peak

Approved, Phase 4 product with multiple related indications in development representing Dompé's most advanced commercial asset.

Pipeline & Clinical Trials

Help build intelligence for Dompé

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong ophthalmology franchise with multiple NGF programs in advanced phases (Phase 3 DED, Phase 4 neurotrophic keratitis with OXERVATE®) offering specialized expertise opportunities
Diversified pipeline of 30 programs across 5 therapeutic areas with 6 Phase 3 programs providing multiple clinical development pathways and exposure to varied disease states
European biotech base with Italian headquarters providing geographic diversity and potential for international career mobility in a research-driven organization

Watch Out For

No current active job openings (activeJobCount = 0) signals potential hiring freeze or limited near-term career entry points
Sparse public financial data, employee count, and recent news limit visibility into company stability, growth trajectory, and organizational health

Generated by Claude from Dompé's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Lubricin

Dry Eye Syndrome

N/A

Clinical Trials (1)

NCT02507934Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye

N/A

Cenegermin Ophthalmic Solution [Oxervate]

Neurotrophic Keratitis

N/A

Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]

Neurotrophic Ulcer

N/A

Clinical Trials (1)

NCT04573647OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

N/A

Cenegemin in the DEFENDO Study

Neurotrophic Keratitis

N/A

Clinical Trials (1)

NCT05552261DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

N/A

Quantitative Sensory Test

Corneal Disease

N/A

Clinical Trials (1)

NCT05758753QST for Corneal Nerve Function

N/A

Lubricin

Dry Eye Syndrome

N/A

Clinical Trials (1)

NCT02510235Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye

N/A

Eye Exam

Sjogren's Syndrome

N/A

Clinical Trials (1)

NCT06364657Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

N/A

Lubricin 20µg/ml

Ocular Discomfort

N/A

Clinical Trials (1)

NCT03031327Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.

N/A

observational study

Sjögren Syndrome

N/A

Clinical Trials (1)

NCT06411132Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

N/A

rhNGF 0.5 µg/mL Sentinel

Healthy

Phase 1

Clinical Trials (1)

NCT01744704Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Phase 1

Cenegermin-Bkbj

Corneal Disease

Phase 1

Clinical Trials (1)

NCT05700864NGF Treatment for Patients With Neuropathic Corneal Pain

Phase 1

DF2755A

no Condition

Phase 1

Clinical Trials (1)

NCT04803396Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A

Phase 1

SCMC-lys powder 1.35 g

Bronchitis

Phase 1

Clinical Trials (1)

NCT02858193Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup

Phase 1

rhNGF 20μg/mL

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03836859Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

Phase 1

Paclitaxel+Reparixin

Metastatic Breast Cancer

Phase 1

Clinical Trials (1)

NCT02001974Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Phase 1

Ladarixin

no Condition

Phase 1

Clinical Trials (1)

NCT04854642A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

Phase 1

rhNGF

Glaucoma

Phase 1

Clinical Trials (1)

NCT02855450Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Phase 1

KSL 40 mg

Pain Disorders

Phase 1

Clinical Trials (1)

NCT02350296Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral Solution

Phase 1

Ketoprofen Lysine Salt combined with Gabapentin

No Condition

Phase 1

Clinical Trials (1)

NCT04802967A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males

Phase 1

rhNGF 60 µg/ml eye drops solution

Retinitis Pigmentosa

Phase 1/2

Clinical Trials (1)

NCT02110225A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

Phase 1/2

rhNGF 10 μg/ml

Neurotrophic Keratitis

Phase 1/2

Clinical Trials (1)

NCT01756456Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

Phase 1/2

Repertaxin

Ischemia-Reperfusion Injury

Phase 2

Clinical Trials (1)

NCT00224406Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

Phase 2

rhNGF 5 μg/mL

Dry Eye Disease

Phase 2

Clinical Trials (1)

NCT06244316A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Phase 2

Ladarixin

Type 1 Diabetes

Phase 2

Clinical Trials (1)

NCT05368402Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Phase 2

Ladarixin

Recent Onset type1 Diabetes

Phase 2

Clinical Trials (1)

NCT04628481A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Phase 2

Reparixin

Breast Cancer

Phase 2

Clinical Trials (1)

NCT01861054Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Phase 2

paclitaxel

Metastatic Breast Cancer

Phase 2

Clinical Trials (1)

NCT02370238A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

Phase 2

reparixin

Myelofibrosis (PMF)

Phase 2

Clinical Trials (1)

NCT05835466Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Phase 2

Alefacept

Atopic Dermatitis

Phase 2

Reparixin

Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT01220856Reparixin in Pancreatic Islet Transplantation

Phase 2

Ladarixin

Diabetes Mellitus, Insulin-Dependent

Phase 2

Clinical Trials (1)

NCT02814838A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Phase 2

DFL24498

Dry Eye Disease (DED)

Phase 2

Clinical Trials (1)

NCT07503886An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Phase 2

Ladarixin

New-onset Type 1 Diabetes

Phase 2

Clinical Trials (1)

NCT04899271A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Phase 2

rhNGF 20 μg/ml

Dry Eye Syndrome

Phase 2

Clinical Trials (1)

NCT03982368A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye